Skip to content
value.today

Kestrel Therapeutics Inc.

🇺🇸 Wayland, Massachusetts, USABiotechnologyFounded 2020
Total raised
$21 M
3 rounds on record
Latest round
$5 M
Jul 2025
First round on record
Dec 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kestrel Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$5 MNo. 3$2 to $10 million

Kestrel Therapeutics Inc.: Raise no. 3, Jul 2025

Investors in this round

6 investors had bought by the notice of Aug 12, 2025: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frank G. Haluska · Executive Officer, Director
  • Andrew G. Phillips · Director
  • Barbara G. Sosnowski · Director
  • Denis G. Patrick · Director
  • Nicholas G. Saccomano · Director
  • Omar G. Khalil · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Frank G. Haluska, President and Chief Executive Officer. Newest notice filed Aug 12, 2025. Read the notice at the SEC.

debt, optionsSEC
Feb 2025$8 MNo. 2$2 to $10 million

Kestrel Therapeutics Inc.: Raise no. 2, Feb 2025

Investors in this round

7 investors had bought by the notice of Feb 21, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $16 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frank G. Haluska · Executive Officer, Director
  • Andrew G. Phillips · Director
  • Barbara G. Sosnowski · Director
  • Denis G. Patrick · Director
  • Nicholas G. Saccomano · Director
  • Omar G. Khalil · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Frank G. Haluska, President and Chief Executive Officer. Newest notice filed Feb 21, 2025. Read the notice at the SEC.

debt, optionsSEC
Dec 2021$8 MNo. 1$2 to $10 million

Kestrel Therapeutics Inc.: Raise no. 1, Dec 2021

Investors in this round

6 investors had bought by the notice of Jan 11, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $40 M offered; $33 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frank G. Haluska · Executive Officer, Director
  • Andrew G. Phillips · Director
  • Denis G. Patrick · Director
  • Omar G. Khalil · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Remaining amounts subject to completion of milestones.”

Signed by Frank G. Haluska, President and Chief Executive Officer. Newest notice filed Jan 11, 2022. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kestrel Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).

    SEC Form D · Aug 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Kestrel Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kestrel Therapeutics Inc.
NameRoleNamed in
Frank G. HaluskaExecutive officerAug 2025
Andrew G. PhillipsDirectorAug 2025
Barbara G. SosnowskiDirectorAug 2025
Denis G. PatrickDirectorAug 2025
Frank G. HaluskaDirectorAug 2025
Nicholas G. SaccomanoDirectorAug 2025
Omar G. KhalilDirectorAug 2025